Bicycle Therapeutics plc NASDAQ:BCYC

Founder-led company

Bicycle Therapeutics stock price today

$7.16
-7.39
-50.79%
Financial Health
0
1
2
3
4
5
6
7
8
9

Bicycle Therapeutics stock price monthly change

-35.79%
month

Bicycle Therapeutics stock price quarterly change

-35.79%
quarter

Bicycle Therapeutics stock price yearly change

-21.35%
year

Bicycle Therapeutics key metrics

Market Cap
994.17M
Enterprise value
341.88M
P/E
-5.47
EV/Sales
23.63
EV/EBITDA
-3.18
Price/Sales
44.02
Price/Book
2.35
PEG ratio
0.12
EPS
-4.45
Revenue
41.59M
EBITDA
-177.73M
Income
-168.14M
Revenue Q/Q
298.66%
Revenue Y/Y
168.39%
Profit margin
-779.35%
Oper. margin
-802.72%
Gross margin
0%
EBIT margin
-802.72%
EBITDA margin
-427.25%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Bicycle Therapeutics stock price history

Bicycle Therapeutics stock forecast

Bicycle Therapeutics financial statements

Average Price Target
Last Year

$39.25

Potential upside: 448.18%

Based on estimate of 4 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Bicycle Therapeutics plc (NASDAQ:BCYC): Profit margin
Jun 2023 11.39M -42.60M -373.81%
Sep 2023 5.35M -49.89M -932.32%
Dec 2023 5.33M -49.09M -921.01%
Mar 2024 19.51M -26.54M -136.01%
Bicycle Therapeutics plc (NASDAQ:BCYC): Debt to assets
Jun 2023 454170000 234.07M 51.54%
Sep 2023 638683000 222.66M 34.86%
Dec 2023 595344000 224.41M 37.69%
Mar 2024 547143000 191.09M 34.93%
Bicycle Therapeutics plc (NASDAQ:BCYC): Cash Flow
Jun 2023 34.09M -277K 12.29M
Sep 2023 -1.02M -502K 234.63M
Dec 2023 -47.28M -51K 386K
Mar 2024 -70.82M -11.99K 1.86M

Bicycle Therapeutics alternative data

Bicycle Therapeutics plc (NASDAQ:BCYC): Employee count
Aug 2023 236
Sep 2023 236
Oct 2023 236
Nov 2023 236
Dec 2023 236
Jan 2024 236
Feb 2024 236
Mar 2024 284
Apr 2024 284
May 2024 284
Jun 2024 284
Jul 2024 284

Bicycle Therapeutics other data

77.36% +0.70%
of BCYC is owned by hedge funds
22.93M +241.37K
shares is hold by hedge funds

Bicycle Therapeutics plc (NASDAQ:BCYC): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 19876
Apr 2024 0 7222
Jul 2024 0 7268
Oct 2024 0 6528
Nov 2024 0 4944
Dec 2024 1485397 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 457,631 $15.34 $7,020,975
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 42,369 $15.34 $650,025
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 566,814 $13.8 $7,824,300
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 244,587 $13.72 $3,356,712
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 59,995 $13.63 $817,672
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 30,241 $13.5 $408,193
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 52,656 $13.8 $726,863
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 22,722 $13.72 $311,837
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 5,573 $13.63 $75,954
Purchase
BAKER BROS. ADVISORS LP director, 10 percent owner:
American Depositary Shares 2,809 $13.5 $37,916
Insider Compensation
Dr. Kevin Lee M.B.A., Ph.D. (1969) Chief Executive Officer & Executive Director
$1,160,000
Dr. Michael Skynner Ph.D., B.sc. Ph.d. (1970) Chief Operating Officer $769,010
Mr. Lee H. Kalowski (1981) Pres & Chief Financial Officer $756,130
Dr. Nigel Crockett Ph.D. (1965) Chief Bus. Officer $568,120
Dr. Dominic Smethurst M.A., M.D. (1974) Chief Medical Officer
$431,700
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE (1951) Co-Founder, Non-Executive Director & Member of Scientific Advisory Board
$40,000
Thursday, 12 December 2024
businesswire.com
Monday, 2 December 2024
businesswire.com
Monday, 25 November 2024
businesswire.com
Thursday, 7 November 2024
seekingalpha.com
Friday, 1 November 2024
businesswire.com
Thursday, 31 October 2024
businesswire.com
Wednesday, 23 October 2024
businesswire.com
Wednesday, 16 October 2024
businesswire.com
Monday, 14 October 2024
zacks.com
Saturday, 14 September 2024
businesswire.com
Friday, 6 September 2024
benzinga.com
Tuesday, 20 August 2024
seekingalpha.com
Friday, 9 August 2024
zacks.com
zacks.com
Thursday, 1 August 2024
businesswire.com
Monday, 22 July 2024
businesswire.com
Thursday, 27 June 2024
zacks.com
Friday, 21 June 2024
zacks.com
Tuesday, 11 June 2024
zacks.com
Monday, 3 June 2024
businesswire.com
Friday, 24 May 2024
zacks.com
zacks.com
Thursday, 23 May 2024
businesswire.com
businesswire.com
Tuesday, 21 May 2024
zacks.com
Monday, 6 May 2024
Zacks Investment Research
Zacks Investment Research
Monday, 25 March 2024
Seeking Alpha
Tuesday, 5 March 2024
Business Wire
Tuesday, 12 September 2023
Zacks Investment Research
  • What's the price of Bicycle Therapeutics stock today?

    One share of Bicycle Therapeutics stock can currently be purchased for approximately $7.16.

  • When is Bicycle Therapeutics's next earnings date?

    Unfortunately, Bicycle Therapeutics's (BCYC) next earnings date is currently unknown.

  • Does Bicycle Therapeutics pay dividends?

    No, Bicycle Therapeutics does not pay dividends.

  • How much money does Bicycle Therapeutics make?

    Bicycle Therapeutics has a market capitalization of 994.17M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 86.52% to 26.98M US dollars.

  • What is Bicycle Therapeutics's stock symbol?

    Bicycle Therapeutics plc is traded on the NASDAQ under the ticker symbol "BCYC".

  • What is Bicycle Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Bicycle Therapeutics?

    Shares of Bicycle Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Bicycle Therapeutics's key executives?

    Bicycle Therapeutics's management team includes the following people:

    • Dr. Kevin Lee M.B.A., Ph.D. Chief Executive Officer & Executive Director(age: 56, pay: $1,160,000)
    • Dr. Michael Skynner Ph.D., B.sc. Ph.d. Chief Operating Officer(age: 55, pay: $769,010)
    • Mr. Lee H. Kalowski Pres & Chief Financial Officer(age: 44, pay: $756,130)
    • Dr. Nigel Crockett Ph.D. Chief Bus. Officer(age: 60, pay: $568,120)
    • Dr. Dominic Smethurst M.A., M.D. Chief Medical Officer(age: 51, pay: $431,700)
    • Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE Co-Founder, Non-Executive Director & Member of Scientific Advisory Board(age: 74, pay: $40,000)
  • Is Bicycle Therapeutics founder-led company?

    Yes, Bicycle Therapeutics is a company led by its founder Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE.

  • How many employees does Bicycle Therapeutics have?

    As Jul 2024, Bicycle Therapeutics employs 284 workers.

  • When Bicycle Therapeutics went public?

    Bicycle Therapeutics plc is publicly traded company for more then 6 years since IPO on 23 May 2019.

  • What is Bicycle Therapeutics's official website?

    The official website for Bicycle Therapeutics is bicycletherapeutics.com.

  • How can i contact Bicycle Therapeutics?

    Bicycle Therapeutics can be reached via phone at +44 1223 261503.

  • What is Bicycle Therapeutics stock forecast & price target?

    Based on 4 Wall Street analysts` predicted price targets for Bicycle Therapeutics in the last 12 months, the avarage price target is $39.25. The average price target represents a 448.18% change from the last price of $7.16.

Bicycle Therapeutics company profile:

Bicycle Therapeutics plc

bicycletherapeutics.com
Exchange:

NASDAQ

Full time employees:

284

Industry:

Biotechnology

Sector:

Healthcare

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Babraham Research Campus
Cambridge, CB22 3AT

CIK: 0001761612
ISIN: US0887861088
CUSIP: 088786108